PECA LABS

PITTSBURGH, PA · Founded 2012 · Medtech · Private

Vascular grafts with regenerative properties for pediatric and adult use

Claim this profile

Follows are private to you and power your alerts

Updated · pecalabs.com

Sector
Medtech
Headquarters
PITTSBURGH, PA
Founded
2012
Latest Form D
$12.8M, Oct 2026
Total capital
$35.7M
Federal grants
$1.5M
4 awards · 2017–2025
Rank in peer group#290 of 477
Private capital raised
$34.2M
10 Form D · last Oct 2026
1 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
4
16 pending · first 2020
Rank in peer group#79 of 477

Capital timeline

201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $35.7M$149K$498K$500K$306K8th Form D$13.9M
201520172019202120232025FEDERAL ↑EQUITY ↓Cumulative $35.7M$149K$498K$500K$306K

Latest events

  • Private capital raisedForm D · SEC · 10th filing$12.8M
  • Private capital raisedForm D · SEC · 9th filing$2.7M
  • Federal grantHealth and Human S · Phase I · A Novel Fully-Polymeric, Biomimetic Prosthetic Mitral Valve Constructed from Clinically-Proven Materials to Improve Durability, Performance, and Overall Outcomes$306K
  • Private capital raisedForm D · SEC · 8th filing$13.9M
  • Private capital raisedForm D · SEC · 7th filing$618K
  • Private capital raisedForm D · SEC · 6th filing$99K
  • Private capital raisedForm D · SEC · 5th filing$587K
  • Private capital raisedForm D · SEC · 4th filing$94K
  • Private capital raisedForm D · SEC · 3rd filing$1.4M
  • Private capital raisedForm D · SEC · 2nd filing$750K
  • Private capital raisedForm D · SEC · 1st filing$1.3M
Show 3 earlier federal awards
  • Federal grantHealth and Human S · Phase II · A Novel Synthetic Vascular Graft Capable of Minimally Invasive Controlled Expansion for Vascular Reconstruction Model$500K
  • Federal grantHealth and Human S · Phase II · A Novel Synthetic Vascular Graft Capable of Minimally Invasive Controlled Expansion for Vascular Reconstruction Model$498K
  • Federal grantHealth and Human S · Phase I · A Novel Synthetic Vascular Graft Capable of Minimally-Invasive Controlled Expansion to Match Somatic Growth in Neonatal and Pediatric Patients$149K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 477 peers

Line = median

Medtech · Device

  • Federal grantsBelow median
  • Granted patents#79 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • C. Douglas BernsteinResearcherExecutive Officer, DirectorLinked by 4 patents
  • Douglas BernsteinResearcherExecutive Officer, DirectorLinked by 4 patents
  • Babs CarryerDirectorNamed in SEC Form D filings
  • Barbara CarryerDirectorNamed in SEC Form D filings
  • Brandon HaynesDirectorNamed in SEC Form D filings
  • David SmithExecutive OfficerNamed in SEC Form D filings
Show all 15 people
  • Dr. Jeffrey CarpenterDirectorNamed in SEC Form D filings
  • Dr. Joseph BavariaDirectorNamed in SEC Form D filings
  • James BrowneDirectorNamed in SEC Form D filings
  • Jeff O?DonnellDirectorNamed in SEC Form D filings
  • Jon KuhnDirectorNamed in SEC Form D filings
  • Michael MoriartyDirectorNamed in SEC Form D filings
  • Rajan KalraDirectorNamed in SEC Form D filings
  • Robert DicksonDirectorNamed in SEC Form D filings
  • Samuel NavarroDirectorNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 20
  • PendingExpandable Implantable ConduitUSPTOApplication 19530080
  • GrantedExpandable Implantable ConduitUSPTOUS 12,551,339
  • PendingTranscatheter Stent And Valve AssemblyUSPTOApplication 18520188
Show all 20 patent records
  • Expandable Implantable ConduitJul 2, 2026 · Application 19530080Pending
  • Expandable Implantable ConduitFeb 17, 2026 · US 12,551,339Granted
  • Transcatheter Stent And Valve AssemblyMar 21, 2024 · Application 18520188Pending
  • Expandable Implantable ConduitJul 22, 2021 · Application 17226731Pending
  • Expandable Implantable ConduitMay 11, 2021 · US 11,000,370Granted
  • Transcatheter Stent And Valve AssemblyAug 27, 2020 · Application 16803892Pending
  • Transcatheter Stent And Valve AssemblyAug 27, 2020 · Application 16803852Pending
  • Transcatheter Stent And Valve AssemblyApr 28, 2020 · US 10,631,979Granted
  • Transcatheter Stent And Valve AssemblyApr 7, 2020 · US 10,610,357Granted
  • Valved Conduit And Method For Fabricating SameJun 21, 2018 · Application 15737186Pending
  • Transcatheter Stent And Valve AssemblyApplication PCTUS2017055939Pending
  • Transcatheter Stent And Valve AssemblyApplication 62532736Pending
  • Polymer Materials With Medical Applications And Methods For ManufacturingApplication PCTUS2025031779Pending
  • Expandable Implantable ConduitApplication PCTUS2017020421Pending
  • Transcatheter Stent And Valve AssemblyApplication 62406175Pending
  • Valved Conduit And Method For Fabricating SameApplication PCTUS2016038302Pending
  • Expandable Implantable ConduitApplication 62302595Pending
  • Polymer Materials With Medical Applications And Methods For ManufacturingApplication 63654676Pending
  • Valved Conduit And Method For Fabricating SameApplication 62181521Pending
  • Polymer Materials With Medical Applications And Methods For ManufacturingApplication 63813526Pending

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .